^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Uterine Cancer

    Related cancers:
    1d
    HIPEC: Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Jan 2027 | Trial primary completion date: Feb 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    2d
    Detecting HPV DNA in Anal and Cervical Cancers (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, University of Chicago | Suspended --> Recruiting
    Enrollment open
    3d
    Immune Network Construction and Prognostic Evaluation of Checkpoint Genes in Endometrial Cancer Using STRING, MCODE, and GEPIA2. (PubMed, Cancer Diagn Progn)
    This in silico immune network highlights checkpoint centered hubs and coordinated immune programs with prognostic relevance in endometrial cancer, providing a rationale for biomarker guided immunotherapy development and patient stratification. Validation in independent cohorts and correlation with clinicopathologic and treatment response data are needed to support clinical translation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PD-L2 (Programmed Cell Death 1 Ligand 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • ICOS (Inducible T Cell Costimulator) • GZMB (Granzyme B) • TBX21 (T-Box Transcription Factor 21) • FOXP3 (Forkhead Box P3) • CD40 (CD40 Molecule) • PRF1 (Perforin 1) • LGALS9 (Galectin 9)
    3d
    Uterine tumors resembling ovarian sex cord tumors: rare case report and literature review. (PubMed, Front Oncol)
    At 20 months the patient is disease-free with regular menses and intact fertility. We review diagnostic clues, differential diagnoses, molecular taxonomy and fertility-sparing strategies, underscoring the value of comprehensive genomic profiling for accurate classification and prognostication of this uncommon uterine tumor.
    Journal • BRCA Biomarker
    |
    ER (Estrogen receptor) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • WT1 (WT1 Transcription Factor) • NCAM1 (Neural cell adhesion molecule 1) • NR4A3 (Nuclear receptor subfamily 4 group A member 3) • SYP (Synaptophysin) • NCOA2 (Nuclear Receptor Coactivator 2)
    |
    TP53 mutation • BRCA2 mutation • BRCA1 mutation
    4d
    Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer: A Nationwide Cohort Study in France. (PubMed, BioDrugs)
    This first real-world study of dostarlimab plus chemotherapy in advanced or recurrent endometrial cancer involved an older, more comorbid, and less selected population with more advanced disease than in RUBY. Survival outcomes were less favorable, but the safety profile was comparable.
    Journal • Real-world evidence • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Jemperli (dostarlimab-gxly)
    4d
    Azenosertib in Uterine Serous Carcinoma: Biomarker Study (clinicaltrials.gov)
    P2, N=25, Recruiting, Joyce Liu, MD | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    MSI-H/dMMR
    |
    azenosertib (ZN-c3)
    5d
    Paraneoplastic Pulmonary Embolism Revealing Metastatic Uterine Carcinosarcoma. (PubMed, Case Rep Oncol Med)
    She was managed with anticoagulation for VTE and initiated on systemic chemotherapy (carboplatin plus paclitaxel), given that surgical cure was not feasible due to metastases. Early identification of the occult cancer allowed appropriate therapy; however, uterine carcinosarcoma carries a poor prognosis once metastatic. Clinicians should maintain a high index of suspicion for hidden malignancy in cases of idiopathic VTE, as timely diagnosis can guide life-saving interventions.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    carboplatin • paclitaxel
    5d
    89Zr/177Lu-Labeled Claudin-6 Antibody Exhibits Effective Targeted Radiodiagnostic and Therapeutic Efficacy in Gynecological Cancers. (PubMed, Eur J Pharm Sci)
    And the 11.1 MBq [¹⁷⁷Lu]Lu-DOTA- IMAB027 group significantly inhibited tumor growth, prolonged survival, and showed lower toxicity than non-radioactive drug treatment groups. ⁸⁹Zr/¹⁷⁷Lu-labeled IMAB027 holding promise as a potentially viable therapeutic approach for clinical management of gynecological cancers.
    Journal
    |
    CLDN6 (Claudin 6)
    |
    ASP1650
    7d
    Clinical Feasibility of the ARCHITECT Applicator in Cervical Cancer Brachytherapy (clinicaltrials.gov)
    P=N/A, N=25, Not yet recruiting, Erasmus Medical Center
    New trial
    8d
    Uterine PEComa With Lymphangioleiomyomatosis (LAM)-Like Features: A Case Report. (PubMed, Case Rep Pathol)
    The patient's postoperative course was uneventful, and follow-up imaging showed no evidence of metastatic disease. This case highlights the importance of integrated morphological, immunohistochemical, and molecular assessment in differentiating uterine mesenchymal neoplasms to guide appropriate clinical management.
    Journal
    |
    TSC1 (TSC complex subunit 1) • CTSK (Cathepsin K)
    8d
    Identification of the Carcinogenic Process from Lobular Endocervical Glandular Hyperplasia to Gastric-Type Adenocarcinoma of the Uterine Cervix via Whole-Exome Sequencing. (PubMed, Cancers (Basel))
    In contrast, SMAD4 and SMAD2 showed frequent loss-of-function-type alterations in GAS, including copy-number loss, but were not detected in LEGH. These findings provide insights into the genomic landscapes of LEGH and GAS and suggest potential molecular markers for this transition, which may inform future diagnostic and therapeutic research.
    Journal
    |
    STK11 (Serine/threonine kinase 11) • ARID1A (AT-rich interaction domain 1A) • SMAD4 (SMAD family member 4) • PTPRT (Protein tyrosine phosphatase receptor type T) • PTPRF (Receptor-type tyrosine-protein phosphatase F) • SMAD2 (SMAD Family Member 2)
    |
    ARID1A mutation • STK11 mutation
    9d
    An Undifferentiated Epithelioid and Spindle Cell Neoplasm of the Uterus Harboring a SMARCA2::CREM Fusion: A Case Report and Review of the Literature. (PubMed, Int J Gynecol Pathol)
    This case contributes additional data to the limited literature on tumors with SMARCA2::CREM fusions. It highlights the potential utility of comprehensive molecular testing, including broader fusion panels or whole-transcriptome sequencing, in the evaluation of diagnostically challenging uterine neoplasms.
    Journal
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CREM (CAMP Responsive Element Modulator) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)